Exclusive Online Content
Antion Announces Granting of Key Technology Patent in the United States
Novel patent solidifies Antion’s position as an industry leader in multiplex engineering of cell and gene therapies….
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement With Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Palisade Bio, Inc. recently announced it has entered into a licensing agreement with Giiant Pharma, Inc., providing the company with the exclusive worldwide rights to develop, manufacture, and commercialize….
Zenas BioPharma Announces Strategic License & Collaboration Agreement With Bristol Myers Squibb
Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases….
SomaLogic Expands Agreement With Novo Nordisk to 2025
Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseases….
Optibrium Acquires BioPharmics, Expanding its 3D Drug Design & Visualization Offering
Optibrium recently announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology…..
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio & Adding Commercial Product
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure….
Bio-Rad Launches First StarBright Red Dye & Extends Range of Antibody Markers Conjugated to StarBright Dyes to Enhance Multiplex Flow Cytometry & Research Capabilities
With 29 additional targets the range also includes dog, cow, and pig targets to support translational models in veterinary immunology research….
Certara Simcyp Group Awarded Two New Grants From US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations…..
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, recently announced global biopharmaceutical company and cell therapy….
Vaxxas Opens World-Class Manufacturing Facility to Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials & First Commercial Products
Vaxxas recently announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The custom-built 60,000-sq-ft Vaxxas Biomedical Facility will serve as….
Foundery Launches Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies
Foundery’s co-development venture studio model aligns first-in-class drug development opportunities with financing and experimental execution to catalyze university discoveries….
Recipharm & Honeywell to Speed Development of Inhalers With Near-Zero Global Warming Potential Propellant
Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care….
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Tiziana Life Sciences Ltd. recently announced the US FDA has cleared the IND application for intranasal foralumab to be studied in Alzheimer’s disease. Foralumab could be a potentially….
BioCorRx Submits Expanded Access Treatment Protocol to FDA for Implantable Biodegradable Naltrexone Pellet for Opioid Use Disorder Treatment
Company hopes in 30 days to begin making its drug candidate available to help patients and address public health crisis….
Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics
Clinigen Limited has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on….
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer & Expanded Pfizer Relationship
Cardiff Oncology, Inc. recently announced plans to advance the company’s lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer….
Recursion Bridges the Protein & Chemical Space With Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion recently announced it has successfully screened the Enamine REAL Space chemical library using its MatchMaker technology, recently acquired from Cyclica, to predict the protein target(s) for….
Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders
Silo Pharma, Inc. recently announced it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in….
Sygnature Discovery Accelerates Global Growth With Major North American Acquisition
Leading integrated drug discovery partner, Sygnature Discovery, recently announced its acquisition of one of North America’s largest discovery Contract Research Organizations, Canada-based….
ProQR Therapeutics & Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen & Ultevursen Ophthalmic Assets
ProQR Therapeutics N.V. and Laboratoires Théa recently announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and….
